Primary source: Inspections and Compliance
The FDA provided a safety signal alerting that multiple pain and arthritis products may contain harmful hidden ingredients, necessitating heightened monitoring and risk assessment.
These safety alerts are critical for drug safety monitoring as they signal potential health risks, informing the need for vigilance in product evaluation and patient safety.
Monitor and reassess affected pain and arthritis products, ensuring compliance with safety reporting protocols for products listed with known hidden ingredients.
Regulatory Intelligence Lead
Review should occur regularly to stay updated with further notifications from the FDA.
Monitor and reassess affected pain and arthritis products, ensuring compliance with safety reporting protocols for products listed with known hidden ingredients.
Recent FDA notifications warn of safety concerns for various pain and arthritis products that contain undisclosed harmful ingredients. This includes alerts for specific products such as Qu Feng Huo Lou Dan and Xian Ling, which pose risks due to hidden pharmaceutical ingredients.
What changed: The FDA provided a safety signal alerting that multiple pain and arthritis products may contain harmful hidden ingredients, necessitating heightened monitoring and risk assessment.
Why it matters: These safety alerts are critical for drug safety monitoring as they signal potential health risks, informing the need for vigilance in product evaluation and patient safety.
Practical implication: Monitor and reassess affected pain and arthritis products, ensuring compliance with safety reporting protocols for products listed with known hidden ingredients.
Published from the regulator source ingestion pipeline after PV impact triage.
Consumers should consult healthcare professionals if using this product and report any adverse effects to FDA’s MedWatch Safety Information.
Healthcare providers and manufacturers must now comply with new reporting obligations for adverse reactions associated with the use of Imaavy and ensure adherence to increased compliance requirements for its administration.
Regulatory intelligence teams should review ongoing studies and compliance with postmarketing requirements for the drugs listed, specifically focusing on their deadlines for completion and the nature of the studies required.
Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
